Business Insider
My Markets Watchlist
Markets Stocks

Halozyme Therapeutics Inc. Stock , HALO

53.98 -0.54 -0.98%
03:59:59 PM EDT 6/13/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/13/2025 the closing price of the Halozyme Therapeutics Inc. share was $54.52 on BTT. Compared to the opening price on Friday 06/13/2025 on BTT of $54.02, this is a gain of 0.92%. Halozyme Therapeutics Inc.'s market capitalization is $5.40 B by 123.22 M shares outstanding.
Is Halozyme Therapeutics stock a Buy, Sell or Hold? Halozyme Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 31 buy ratings, 7 hold ratings, and 0 sell ratings.
What was the 52-week low for Halozyme Therapeutics stock? The low in the last 52 weeks of Halozyme Therapeutics stock was 42.02. According to the current price, Halozyme Therapeutics is 128.46% away from the 52-week low.
What was the 52-week high for Halozyme Therapeutics stock? The high in the last 52 weeks of Halozyme Therapeutics stock was 70.50. According to the current price, Halozyme Therapeutics is 76.57% away from the 52-week high.
What are analysts forecasts for Halozyme Therapeutics stock? The 38 analysts offering price forecasts for Halozyme Therapeutics have a median target of 58.92, with a high estimate of 75.00 and a low estimate of 40.00. The median estimate represents a 91.61 difference from the last price of 53.98.

Halozyme Therapeutics Stock Snapshot

46.02
Bid
100.00
Bid Size
61.72
Ask
100.00
Ask Size
6/13/2025
Date
3:59 PM
Time
46,188.00
Volume
54.52
Prev. Close
54.02
Open
6.65 B
Market Cap in USD
123.22 M
Number of Shares
123.22 M
Total Number of Shares
53.82
Day Low
54.47
Day High
53.98
42.02
52 Week Low
70.50
52 Week High
53.98
0.00
Dividend in USD
0.00
Dividend Yield
13.93
P/E Ratio
98.90
Free Float in %
3.43
EPS in USD
2.95
Book Value per Share in USD
3.70
Cash Flow per Share in USD

Historical Prices for Halozyme Therapeutics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Halozyme Therapeutics Analyst Data

Total Analysts: 38
Buy Ratings: 31 Neutral Ratings: 7 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 40.00 Median: 58.92 Highest: 75.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Halozyme Therapeutics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/29/25 H.C. Wainwright & Co.
Maintained Buy $72
05/14/25 Morgan Stanley
Downgraded to Hold $62
05/07/25 Wells Fargo & Co
Maintained Hold $65
04/25/25 H.C. Wainwright & Co.
Maintained Buy $72
04/21/25 J.P. Morgan
Maintained Hold $58
03/06/25 H.C. Wainwright & Co.
Maintained Buy
02/20/25 The Benchmark Company
Maintained Buy $75
02/19/25 H.C. Wainwright & Co.
Maintained Buy $72
02/04/25 H.C. Wainwright & Co.
Maintained Buy $70
07/22/24 Goldman Sachs
Maintained Hold $49
07/16/24 H.C. Wainwright & Co.
Maintained Buy $65
06/25/24 The Benchmark Company
Maintained Buy $60
06/24/24 H.C. Wainwright & Co.
Maintained Buy $65
06/07/24 Wells Fargo & Co
Maintained Buy $58
06/07/24 H.C. Wainwright & Co.
Maintained Buy $65
06/07/24 Piper Sandler
Downgraded to Hold $51
06/04/24 H.C. Wainwright & Co.
Maintained Buy $50
05/22/24 H.C. Wainwright & Co.
Maintained Buy $50
05/08/24 JMP Securities LLC
Maintained Buy $71
05/07/24 H.C. Wainwright & Co.
Maintained Buy $50
04/30/24 H.C. Wainwright & Co.
Maintained Buy $50
04/17/24 H.C. Wainwright & Co.
Maintained Buy $50
04/16/24 The Benchmark Company
Maintained Buy $50
02/21/24 JMP Securities LLC
Maintained Buy $72
02/21/24 H.C. Wainwright & Co.
Maintained Buy $50
01/19/24 The Benchmark Company
Maintained Buy $50
01/18/24 JMP Securities LLC
Maintained Buy $72
01/18/24 Goldman Sachs
Maintained Hold $40
01/18/24 H.C. Wainwright & Co.
Maintained Buy $48
12/26/23 Morgan Stanley
Maintained Buy $59
10/20/23 The Benchmark Company
Maintained Buy $50
10/19/23 H.C. Wainwright & Co.
Maintained Buy $61
10/09/23 H.C. Wainwright & Co.
Maintained Buy $60
09/08/23 H.C. Wainwright & Co.
Maintained Buy $60
08/30/23 H.C. Wainwright & Co.
Maintained Buy $60
08/15/23 H.C. Wainwright & Co.
Maintained Buy $60
08/10/23 Morgan Stanley
Maintained Buy $61
07/24/23 H.C. Wainwright & Co.
Maintained Buy $61
07/24/23 Goldman Sachs
Downgraded to Hold $45

Halozyme Therapeutics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 1,245 1,481 1,701 1,966 1,818
Dividend - - - - -
Dividend Yield (in %) - - - - -
EPS 5.35 7.16 9.02 10.02 9.01
P/E Ratio 10.08 7.53 5.99 5.39 5.99
EBIT 742 951 1,145 1,308 1,147
EBITDA 815 1,015 1,203 1,440 1,298
Net Profit 626 778 913 1,049 925
Net Profit Adjusted 673 888 1,082 1,173 1,046
Pre-Tax Profit 755 972 1,159 1,327 1,171
Pre-Tax Profit Reported - - - - -
EPS (Non-GAAP) ex. SOE 5.35 7.16 9.02 10.02 9.01
EPS (GAAP) 4.81 6.14 7.23 8.71 7.86
Gross Income 993 1,258 1,496 - -
Cash Flow from Investing -2 -2 -2 - -
Cash Flow from Operations 622 870 1,067 - -
Cash Flow from Financing -400 -150 - - -
Cash Flow per Share 5.36 7.10 8.68 - -
Free Cash Flow 615 864 1,054 - -
Free Cash Flow per Share - - - - -
Book Value per Share 6.45 11.99 19.26 - -
Net Debt 787 43 -872 - -
Research & Development Exp. 63 72 66 66 66
Capital Expenditure 2 2 2 - -
Selling, General & Admin. Exp. 161 160 153 178 179
Shareholder’s Equity 616 1,368 2,467 - -
Total Assets 2,318 3,073 4,174 - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 6 6 6 5
Average Estimate - 1.213 USD 1.433 USD 5.354 USD 7.164 USD
Year Ago - 0.734 USD 1.080 USD 3.502 USD -
Publish Date - 8/12/2025 11/10/2025 - -
Revenue Estimates
No. of Analysts - 6 6 8 7
Average Estimate - 283 USD 331 USD 1,245 USD 1,481 USD
Year Ago - 231 USD 290 USD 1,015 USD -
Publish Date - 8/12/2025 11/10/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 1,015.32 829.25 660.12 443.31 267.59 195.99 151.86
Change of sales in % 22.44 25.62 48.91 65.67 36.53 29.06 -52.04
Gross profit on sales 784.86 563.12 477.66 361.90 224.23 150.45 141.73
Gross profit on sales change in % 39.38 17.89 31.99 61.40 49.04 6.15 -50.35
Operating income 551.48 337.57 289.43 275.90 144.26 -36.65 -113.53
Operating income change in % 63.36 16.63 4.90 91.26 - 67.72 -
Income before tax 557.13 348.33 248.92 248.52 129.30 -72.25 -123.99
Income before tax change in % 59.94 39.94 0.16 92.20 - 41.73 -
Income after tax 444.09 281.59 202.13 402.71 129.09 -72.24 -80.33
Income after tax change in % 57.71 39.31 -49.81 211.97 - 10.07 -

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 1,800.06 1,649.46 1,671.71 907.48 428.88 474.11 191.36
Long-term liabilities per share 13.49 12.12 11.40 5.75 0.06 2.84 0.29
Equity 363.82 83.81 169.80 196.95 151.05 91.77 248.89
Equity change in % 334.11 -50.64 -13.79 30.39 64.60 -63.13 19.45
Balance sheet total 2,163.88 1,733.27 1,841.51 1,104.43 579.92 565.87 440.25
Balance sheet total change in % 24.84 -5.88 66.74 90.44 2.48 28.54 -15.33

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 7.84 6.18 4.69 3.02 1.89 1.36 1.06
P/E ratio (year end quote, basic EPS) 13.93 17.61 39.58 14.66 46.81 - -
P/E ratio (year end quote, diluted EPS) 13.93 17.61 39.58 14.66 46.81 - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 16.81 4.84 9.22 17.83 26.05 16.22 56.53
Debt ratio in % 83.19 95.16 90.78 82.17 73.95 83.78 43.47

Halozyme Therapeutics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Henderson Jeffrey William 04/30/2025 4,165.00 32,776.00 n/a Buy No
Miyashita Akiko Moni 04/30/2025 4,165.00 24,937.00 n/a Buy No
Duncan Barbara Gayle 04/30/2025 4,165.00 19,919.00 n/a Buy No
Krishnan Mahesh 04/30/2025 4,165.00 10,666.00 n/a Buy No
Posard Matthew L. 04/30/2025 4,165.00 74,039.00 n/a Buy No
Henderson Jeffrey William 04/27/2025 200.00 28,611.00 61.00 Sell No
Henderson Jeffrey William 04/27/2025 4,297.00 28,811.00 60.34 Sell No
Henderson Jeffrey William 03/31/2025 503.00 33,108.00 64.05 Sell No
Henderson Jeffrey William 03/02/2025 1,795.00 36,816.00 57.93 Sell No
Henderson Jeffrey William 03/02/2025 3,205.00 33,611.00 59.12 Sell No
LaBarre Michael J. 02/26/2025 100.00 173,756.00 58.74 Sell No
LaBarre Michael J. 02/26/2025 1,597.00 173,856.00 58.25 Sell No
LaBarre Michael J. 02/25/2025 9,400.00 176,053.00 58.09 Sell No
LaBarre Michael J. 02/25/2025 600.00 175,453.00 58.65 Sell No
LaBarre Michael J. 02/24/2025 9,300.00 186,153.00 58.01 Sell No
LaBarre Michael J. 02/24/2025 700.00 185,453.00 58.67 Sell No
Torley Helen 02/22/2025 12,081.00 733,719.00 57.75 Sell No
Snyder Mark Howard 02/22/2025 3,775.00 28,489.00 57.75 Sell No
LaBrosse Nicole 02/22/2025 3,601.00 31,900.00 57.75 Sell No
LaBarre Michael J. 02/22/2025 2,410.00 195,453.00 57.75 Sell No
Torley Helen 02/22/2025 22,436.00 745,800.00 n/a Buy No
Snyder Mark Howard 02/22/2025 7,012.00 32,264.00 n/a Buy No
LaBrosse Nicole 02/22/2025 6,688.00 35,501.00 n/a Buy No
LaBarre Michael J. 02/22/2025 4,747.00 197,863.00 n/a Buy No
LaBarre Michael J. 02/15/2025 8,721.00 188,008.00 58.29 Sell No

Halozyme Therapeutics Dividend Calendar

Date Name Dividend *yield Currency
2024 Halozyme Therapeutics Inc. 0.00 0.00 USD
2023 Halozyme Therapeutics Inc. 0.00 0.00 USD
2022 Halozyme Therapeutics Inc. 0.00 0.00 USD
2021 Halozyme Therapeutics Inc. 0.00 0.00 USD
2020 Halozyme Therapeutics Inc. 0.00 0.00 USD
2019 Halozyme Therapeutics Inc. 0.00 0.00 USD
2018 Halozyme Therapeutics Inc. 0.00 0.00 USD
2017 Halozyme Therapeutics Inc. 0.00 0.00 USD
2016 Halozyme Therapeutics Inc. 0.00 0.00 USD
2015 Halozyme Therapeutics Inc. 0.00 0.00 USD
2014 Halozyme Therapeutics Inc. 0.00 0.00 USD
2013 Halozyme Therapeutics Inc. 0.00 0.00 USD
2012 Halozyme Therapeutics Inc. 0.00 0.00 USD
2011 Halozyme Therapeutics Inc. 0.00 0.00 USD
2010 Halozyme Therapeutics Inc. 0.00 0.00 USD
2009 Halozyme Therapeutics Inc. 0.00 0.00 USD
*Yield of the Respective Date

Halozyme Therapeutics Calendar

Event Estimate Info Date
Earnings Report 1.213 USD Q2 2025 Earnings Release 08/12/2025
Earnings Report 1.433 USD Q3 2025 Earnings Release 11/10/2025
Earnings Report 1.660 USD Q4 2025 Earnings Release 02/24/2026
Earnings Report 1.525 USD Q1 2026 Earnings Release 05/12/2026

Halozyme Therapeutics Past Events

Event Actual EPS Info Date
Earnings Report 0.930 USD Q1 2025 Earnings Release 05/06/2025
Annual General Meeting 3.430 USD Annual General Meeting 05/01/2025
Earnings Report 1.060 USD Q4 2024 Earnings Release 02/18/2025
Earnings Report 1.050 USD Q3 2024 Earnings Release 10/31/2024
Earnings Report 0.720 USD Q2 2024 Earnings Release 08/06/2024
Earnings Report 0.600 USD Q1 2024 Earnings Release 05/07/2024
Annual General Meeting 2.100 USD Annual General Meeting 04/25/2024
Earnings Report 0.650 USD Q4 2023 Earnings Release 02/20/2024
Earnings Report 0.610 USD Q3 2023 Earnings Release 11/06/2023
Earnings Report 0.560 USD Q2 2023 Earnings Release 08/08/2023
Earnings Report 0.290 USD Q1 2023 Earnings Release 05/09/2023
Annual General Meeting 1.440 USD Annual General Meeting 05/05/2023
Earnings Report 0.420 USD Q4 2022 Earnings Release 02/21/2023
Earnings Report 0.440 USD Q3 2022 Earnings Release 11/08/2022
Earnings Report 0.160 USD Q2 2022 Earnings Release 08/09/2022
Earnings Report 0.430 USD Q1 2022 Earnings Release 05/10/2022
Annual General Meeting 2.740 USD Annual General Meeting 05/05/2022
Earnings Report 0.460 USD Q4 2021 Earnings Release 02/22/2022

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »